Lifecore Biomedical Inc

LFCR is in a Stage 4 decline with a sequence of lower highs and lower lows, confirmed by the down-sloping EMAs. Active Lower Highs & Lower Lows pattern underscores supply dominance and maintains downward bias. Short-term timing remains neutral as price pulls into declining EMAs without clear rejection or follow-through. Execution is deferred, awaiting rallies into the EMA zone and prior resistance for disciplined sell entries.

• ↑High profitability (score 0.85) and Q1 gross profit of $5.4 M
• ↑Ten late-stage programs expected FDA approval by 2028
• ↓Q1 net loss $16.2 M and negative earnings yield signal profitability issues